Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373176 | 0.88 | LPL (0.44) | LPLLIPGFFAR1F11P2RX7 | |
| SCHEMBL626260 | 0.81 | LPL (0.39) | LPLLIPGFFAR1F11P2RX7 | |
| SCHEMBL31219289 | 0.81 | LPL (0.39) | LPLLIPGFFAR1F11P2RX7 | |
| SCHEMBL25815214 | 0.79 | LIPG (0.44) | LPLLIPGFFAR1F11P2RX7 | |
| SCHEMBL925705 | 0.79 | LPL (0.38) | LPLLIPGFFAR1F11P2RX7 | |
| SCHEMBL791063 | 0.79 | F11 (0.38) | LPLLIPGFFAR1F11P2RX7 | |
| SCHEMBL4163085 | 0.79 | FFAR1 (0.40) | LPLLIPGFFAR1F11P2RX7 | |
| SCHEMBL975905 | 0.79 | LPL (0.49) | LPLLIPGFFAR1F11P2RX7 | |
| SCHEMBL1302755 | 0.79 | LPL (0.38) | LPLLIPGFFAR1F11P2RX7 | |
| SCHEMBL1302760 | 0.78 | MKNK1 (0.39) | LPLLIPGFFAR1F11CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018067762-A2 | HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2018-04-12 | — | — | WO | disclosed |